Ann: Preliminary Final Report FY2021 App 4E and Announcement, page-10

Yes, this stock seems to starve on lack of news, making a few nervous.

MODULATE results are a little overdue but remember they were originally scheduled for 2023 - so still ok in my book, although they do need to address this very soon with an update as the delay is a poor look and impacts confidence.

Bionomics Ltd (ASX:BNO) (OTCMKTS:BNOEF) (FRA:B1N) has completed the MODULATE clinical trial, an experimental phase 2 trial of its drug candidate BNC105 in combination with Bristol Myers Squibb’s (NYSE:BMY) nivolumab, in patients with metastatic colorectal cancer.The trial sponsor, the Australasian Gastro-Intestinal Trials Group (AGITG), is expecting that results will be ready in the second quarter of 2021, which is ahead of the previously announced timeline for topline data of early 2023.

ATTUNE - I can't find anything more on since the July announcement.
It's a 12 week trial with topline results expected in 2023.
Have to admit that it does seem a long time away without any updates on when it is likely start - or if it has started?
Some progress updates would be useful and help avoid the shareholder angst.

Science seems to make sense to me and so I'm sticking around a bit longer.